Vaccine Responses to SARS-CoV-2 and Other Emerging Infectious Diseases

Study Description: This protocol will enroll up to 200 adults per year who are scheduled to be vaccinated against severe acute respiratory syndromecorona virus 2 (SARS-CoV-2) or other emerging pathogens. Participants will provide blood samples prior to and serially aftervaccination. The blood will be used to perform research studies of the immune response to primary (new) and secondary (booster) vaccines. Objectives: Primary Objective: Characterize longitudinal serologic and cellular responses to vaccination to SARS-CoV-2 and other emerging infections. Secondary Objectives: 1. Evaluate baseline correlates of immune response to vaccination. 2. Correlate cellular and serologic responses after vaccination. 3. For vaccines that require two or more doses; characterize the immunologic responses following both the primary (new) and the secondary (booster) dose(s). 4. Evaluate the longevity of immune responses to primary (new) and secondary (booster) vaccination. Endpoints: Primary Endpoint: Establish immunologically well characterized cohorts of primary (new) and secondary (booster) vaccinated individuals. Secondary Endpoints: Establish factors associated with longevity of serologic and cellular responses to primary (new) and secondary (booster) vaccination.